Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for-
Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for-
Duloxetine Hydrochloride is an orally administered selective serotonin and norepinephrine reuptake inhibitor (SSNRI). Duloxetine is a less powerful dopamine reuptake inhibitor. In vitro, dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors have no appreciable affinity for duloxetine. Monoamine oxidase is not inhibited by duloxetine (MAO). Duloxetine hydrochloride is well absorbed when taken orally. Duloxetine is primarily eliminated by hepatic metabolism.
Major Depressive Disorder (MDD)-
Generalized Anxiety Disorder (GAD)-
Diabetic Peripheral Neuropathic Pain (DPNP)-
Fibromyalgia-
Chronic Musculoskeletal Pain-
Some patients may benefit from starting at 30 mg once daily. There is no evidence that doses greater than 60 mg/day confers an additional benefit, while some adverse reactions were observed to be dose-dependent. A gradual dose reduction is recommended to avoid discontinuation symptoms.
Duloxetine metabolism is controlled by the CYP1A2 and CYP2D6 isozymes. The AUC, Cmax, and t of Duloxetine were all enhanced when it was given with fluvoxamine, a powerful CYP1A2 inhibitor. Cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin are examples of medicines that impede CYP1A2 metabolism, therefore these combinations should be avoided. Because CYP2D6 is involved in Duloxetine metabolism, combining Duloxetine with CYP2D6 inhibitors may result in increased Duloxetine concentrations.
Patients who have a known hypersensitivity to duloxetine or any of its inactive components should avoid it. Duloxetine is not approved for the treatment of bipolar disorder. Patients with a history of heavy drinking or symptoms of chronic liver damage should not be prescribed duloxetine. Duloxetine has been linked to an increased risk of mydriasis in clinical trials, thus it should be used with caution in individuals with managed narrow-angle glaucoma.
Nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased perspiration, hyperhidrosis, and asthenia were the most commonly reported side effects in Duloxetine hydrochloride patients. It may cause a small rise in blood pressure. Between Duloxetine-treated and placebo-treated patients, there were no clinically significant variations in QT, PR, and QRS intervals.
Pregnancy group C. There are no adequate and well-controlled studies in pregnant women; therefore, duloxetine should only be used during pregnancy if there is potential benefit to the fetus.
Labor and Delivery: The effect of duloxetine on labor and delivery in humans is unknown. Duloxetine should only be used during labor and delivery if the potential benefit outweighs the potential risk to the fetus.
Breast-feeding: It is not known whether duloxetine and / or its metabolites are excreted in human milk, but breast-feeding while taking duloxetine is not recommended
All patients using antidepressants for any reason should be constantly monitored and evaluated for signs of clinical deterioration, suicidality, or unexpected changes in behavior, especially during the first few months of treatment or when doses are changed. Prior to starting treatment, blood pressure should be checked, and it should be checked again at regular intervals during treatment. Patients should be warned about the risk of bleeding when taking Duloxetine with NSAIDs, aspirin, or other coagulation-disrupting medications. Duloxetine should be prescribed with care in patients with a history of a seizure disorder.
Serotonin-norepinephrine reuptake inhibitor (SNRI)
Reviews
There are no reviews yet.